[go: up one dir, main page]

PT904081E - Suspensoes aquosas de esteres de acidos gordos de 9-hidroxirisperidona - Google Patents

Suspensoes aquosas de esteres de acidos gordos de 9-hidroxirisperidona

Info

Publication number
PT904081E
PT904081E PT97923912T PT97923912T PT904081E PT 904081 E PT904081 E PT 904081E PT 97923912 T PT97923912 T PT 97923912T PT 97923912 T PT97923912 T PT 97923912T PT 904081 E PT904081 E PT 904081E
Authority
PT
Portugal
Prior art keywords
aquos
suspensions
fatty acids
acids esters
hydroxyrisperidone fatty
Prior art date
Application number
PT97923912T
Other languages
English (en)
Inventor
Roger Carolus August Embrechis
Marc Karel Jozef Francois
Herman Karel Borghijs
Johan Monbaliu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT904081(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT904081E publication Critical patent/PT904081E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PT97923912T 1996-05-20 1997-05-12 Suspensoes aquosas de esteres de acidos gordos de 9-hidroxirisperidona PT904081E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20

Publications (1)

Publication Number Publication Date
PT904081E true PT904081E (pt) 2002-04-29

Family

ID=8224016

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97923912T PT904081E (pt) 1996-05-20 1997-05-12 Suspensoes aquosas de esteres de acidos gordos de 9-hidroxirisperidona

Country Status (37)

Country Link
US (1) US6077843A (pt)
EP (1) EP0904081B1 (pt)
JP (1) JP3274687B2 (pt)
KR (1) KR100358373B1 (pt)
CN (1) CN1093762C (pt)
AR (1) AR007194A1 (pt)
AT (1) ATE208619T1 (pt)
AU (1) AU715572B2 (pt)
BG (1) BG62684B1 (pt)
BR (1) BR9706824B8 (pt)
CA (1) CA2236691C (pt)
CY (2) CY2270B1 (pt)
CZ (1) CZ291284B6 (pt)
DE (2) DE122011100027I1 (pt)
DK (1) DK0904081T3 (pt)
EA (1) EA000536B1 (pt)
EE (1) EE03594B1 (pt)
ES (1) ES2167745T3 (pt)
FR (1) FR11C0035I2 (pt)
HR (1) HRP970276B1 (pt)
HU (2) HU224025B1 (pt)
ID (1) ID16927A (pt)
IL (1) IL124551A (pt)
LU (1) LU91842I2 (pt)
MX (1) MX9804816A (pt)
MY (1) MY126302A (pt)
NO (2) NO315931B1 (pt)
NZ (1) NZ330369A (pt)
PL (1) PL188309B1 (pt)
PT (1) PT904081E (pt)
SI (1) SI0904081T1 (pt)
SK (1) SK284013B6 (pt)
TR (1) TR199800923T2 (pt)
TW (1) TW487572B (pt)
UA (1) UA61898C2 (pt)
WO (1) WO1997044039A1 (pt)
ZA (1) ZA974331B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CA2321924A1 (en) * 1998-02-25 1999-09-02 Abbott Laboratories Butorphanol sustained release formulations
US6342488B1 (en) 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
EE05022B1 (et) 1999-03-31 2008-06-16 Janssen Pharmaceutica N.V. Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
PT1783118E (pt) * 2000-08-14 2008-08-19 Teva Pharma Preparação de risperidona
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
RU2321391C2 (ru) * 2002-07-29 2008-04-10 Алза Корпорейшн Способы и лекарственные формы для контролируемой доставки палиперидона
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
PT1675573E (pt) 2003-10-23 2008-12-30 Otsuka Pharma Co Ltd Formulação de iripiprazole injectável estéril de libertação controlada e um processo para a sua preparação
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CA2553254C (en) * 2004-01-12 2013-12-17 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20080214808A1 (en) 2005-04-25 2008-09-04 Thomas Frederik Ernestine Spittaels Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CN101641353B (zh) * 2007-04-19 2012-05-23 长春健欣生物医药科技开发有限公司 用于治疗精神疾病的新颖化合物及其制备方法和用途
CN101715340A (zh) 2007-04-23 2010-05-26 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
AU2008340101C1 (en) 2007-12-19 2025-03-06 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters
US20090209757A1 (en) * 2008-01-10 2009-08-20 Santiago Ini Processes for the preparation and purification of paliperidone palmitate
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
KR101760953B1 (ko) 2008-09-04 2017-07-24 아밀린 파마슈티칼스, 엘엘씨. 비-수성 담체를 이용한 서방성 제형물
KR102093612B1 (ko) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
NZ599558A (en) 2009-10-30 2014-09-26 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
US20120259116A1 (en) * 2009-12-17 2012-10-11 Rajiv Kumar Novel Process for the Preparation of Paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Viiv醫療保健公司 醫藥組合物
WO2012053654A1 (en) 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8940749B2 (en) 2011-05-31 2015-01-27 Ramamohan Rao Davuluri Preparation of 3-[2-[4-((6-fluoro-1, 2-benzisoxazol-3-yl)-l-piperidinyl)-6, 7, 8, 9-tetrahydor-9-hydroxy-2-methyl-4H-pyrido[ 1, 2-A]-pyrimidin-4-one(paliperidone) and paliperidone palmitate
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EA037185B1 (ru) 2015-04-07 2021-02-17 Янссен Фармацевтика Н.В. Способ лечения психоза, шизофрении или биполярного расстройства
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CA3049034A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
LT4025187T (lt) 2020-11-30 2024-02-12 Janssen Pharmaceutica Nv Dozavimo režimai, susiję su prailginto atpalaidavimo injekcinėmis paliperidono vaisto formomis
IL303253A (en) 2020-11-30 2023-07-01 Janssen Pharmaceutica Nv Dosing regimens associated with delayed-release injectable formulations of paliperidone
JP2023551009A (ja) 2020-11-30 2023-12-06 ヤンセン ファーマシューティカ エヌ.ベー. 持続放出パリペリドン注射可能製剤に関連する投与レジメン
AU2021388842A1 (en) 2020-11-30 2023-07-13 Janssen Pharmaceutica Nv Methods for ensuring resuspension of paliperidone palmitate formulations
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
JP2024532195A (ja) 2021-08-20 2024-09-05 ヤンセン ファーマシューティカ エヌ.ベー. 持続放出パリペリドン注射可能製剤に関連する投与レジメン

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
SG47445A1 (en) * 1993-11-19 1998-04-17 Janssen Pharmaceutica Nv Microencapsulated 3-piperidinyl-substituted1 1 2-benzisoxazoles and 1 2-benzisothiazoles
CA2474701C (en) * 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradeable microparticles containing a biologically active agent
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
ES2157442T3 (es) * 1995-06-06 2001-08-16 Aventis Pharma Inc Derivados de benzoisoxazol y de indazol, utilizados como agentes neurolepticos.
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
FR11C0035I2 (fr) 2013-08-16
EA199800531A1 (ru) 1998-12-24
US6077843A (en) 2000-06-20
DE122011100027I1 (de) 2011-11-17
CN1093762C (zh) 2002-11-06
JP3274687B2 (ja) 2002-04-15
BR9706824A (pt) 1999-03-23
WO1997044039A1 (en) 1997-11-27
NZ330369A (en) 2000-04-28
CZ291284B6 (cs) 2003-01-15
IL124551A (en) 2001-08-26
PL188309B1 (pl) 2005-01-31
HU224025B1 (hu) 2005-05-30
CY2011011I2 (el) 2016-12-14
EE9800136A (et) 1998-10-15
CA2236691A1 (en) 1997-11-27
HK1017852A1 (en) 1999-12-03
LU91842I2 (fr) 2011-09-20
TW487572B (en) 2002-05-21
JP2000513718A (ja) 2000-10-17
EP0904081A1 (en) 1999-03-31
DK0904081T3 (da) 2002-02-25
BG102443A (en) 1999-06-30
NO2011015I1 (no) 2011-09-19
NO981984D0 (no) 1998-04-30
CA2236691C (en) 2007-01-02
TR199800923T2 (xx) 1999-09-21
SI0904081T1 (en) 2002-04-30
HRP970276B1 (en) 2002-04-30
CN1206347A (zh) 1999-01-27
UA61898C2 (en) 2003-12-15
HUS1100013I1 (hu) 2017-03-28
NO981984L (no) 1998-11-19
SK284013B6 (sk) 2004-08-03
MX9804816A (es) 1998-10-31
KR100358373B1 (ko) 2003-02-11
HRP970276A2 (en) 1998-04-30
SK62098A3 (en) 2000-04-10
BR9706824B8 (pt) 2015-02-18
MY126302A (en) 2006-09-29
IL124551A0 (en) 1998-12-06
NO315931B1 (no) 2003-11-17
ATE208619T1 (de) 2001-11-15
BG62684B1 (bg) 2000-05-31
ES2167745T3 (es) 2002-05-16
CY2270B1 (en) 2003-07-04
HUP9901319A3 (en) 1999-11-29
AU2955997A (en) 1997-12-09
ZA974331B (en) 1998-11-19
NO2011015I2 (no) 2013-03-11
AR007194A1 (es) 1999-10-13
DE69708284T2 (de) 2002-07-25
AU715572B2 (en) 2000-02-03
CY2011011I1 (el) 2016-12-14
HUP9901319A2 (hu) 1999-08-30
EA000536B1 (ru) 1999-10-28
CZ140198A3 (cs) 1999-04-14
PL327995A1 (en) 1999-01-04
KR19990067603A (ko) 1999-08-25
EE03594B1 (et) 2002-02-15
FR11C0035I1 (pt) 2011-07-10
EP0904081B1 (en) 2001-11-14
DE69708284D1 (de) 2001-12-20
ID16927A (id) 1997-11-20

Similar Documents

Publication Publication Date Title
PT904081E (pt) Suspensoes aquosas de esteres de acidos gordos de 9-hidroxirisperidona
PT1033987E (pt) Suspensoes aquosas de esteres de 9-hidroxirrisperidona com acidos gordos da ordem dos submicrons
PL331700A1 (en) Method of obtaining fatty acid esters
EP0736545A3 (en) Ester of dextrin and fatty acids and its use
PT823895E (pt) Esteres de acidos gordos como composto bioactivos
HRP20041057A2 (en) Method and system for the esterification of fatty acids
ID17964A (id) Pembuatan ester surfaktan
EE200000241A (et) 8-metoksükinoloonkarboksüülhapete valmistamismeetod
DK0718275T3 (da) Kvaternære triethanolaminfedtsyreestere
FR2722798B1 (fr) 1procede de production d'acides gras2plantes oleagineuses
GB9620248D0 (en) Esters of unsaturated fatty acids
PL332853A1 (en) Method of obtaining alpha-alkoxy-alpha-trifluoromethyl-acrylacetic esters and acids
PT854142E (pt) Processo para preparacao de esteres de acidos 1-alquilpirazol-5-carboxilicos
GB9705102D0 (en) Presentation of fatty acids
DE69515479D1 (de) Fettsäureester von verätherten polyalkoholen
BR9703374A (pt) Misturas tensoativas de acilovialcanossulfonatos e ésteres de ácidos graxos
AU3645195A (en) Modified polyunsaturated fatty acids
GB9403906D0 (en) Reduced absorption of fatty acids
ATA199097A (de) Verfahren zur herstellung von fettsäuremethylester und anlage zur durchführung des verfahrens
PL331949A1 (en) Method of obtaining methyl esters of fatty acids
PL310213A1 (en) Method of obtaining benzoic esters
SK2252U (sk) Zariadenie na kontinuálnu esterifikáciu mastných kyselín